174 related articles for article (PubMed ID: 11455553)
1. Molecular markers in Paget disease of the breast.
Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
[TBL] [Abstract][Full Text] [Related]
2. The role of p53 and Ki67 in Paget's disease of the vulva and the breast.
Ellis PE; Fong LF; Rolfe KJ; Crow JC; Reid WM; Davidson T; MacLean AB; Perrett CW
Gynecol Oncol; 2002 Aug; 86(2):150-6. PubMed ID: 12144821
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization.
Wachter DL; Wachter PW; Fasching PA; Beckmann MW; Hack CC; Riener MO; Hartmann A; Strehl JD
Arch Pathol Lab Med; 2019 Feb; 143(2):206-211. PubMed ID: 30124327
[TBL] [Abstract][Full Text] [Related]
4. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
Soslow RA; Carlson DL; Horenstein MG; Osborne MP
Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma.
Anderson JM; Ariga R; Govil H; Bloom KJ; Francescatti D; Reddy VB; Gould VE; Gattuso P
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):120-4. PubMed ID: 12777994
[TBL] [Abstract][Full Text] [Related]
6. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
9. "Extramammary-Type" Paget Disease of the Breast.
Fernandez-Flores A; Eraña I; Cuevas J
Am J Dermatopathol; 2018 Oct; 40(10):711-720. PubMed ID: 30234560
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
Erdem O; Dursun A; Coşkun U; Günel N
Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
[TBL] [Abstract][Full Text] [Related]
11. Expression of Cox-2 and Bcl-2 in Paget's disease of the breast.
Alikanoglu AS; Yildirim M; Suren D; Tutus B; Kaya V; Topal CS; Keser S; Karadayi AN; Kapucuoglu FN; Ayva S; Gunduz S
Asian Pac J Cancer Prev; 2015; 16(3):1041-5. PubMed ID: 25735328
[TBL] [Abstract][Full Text] [Related]
12. Useful immunohistochemical markers for distinguishing Paget cells from Toker cells.
Park S; Suh YL
Pathology; 2009; 41(7):640-4. PubMed ID: 20001343
[TBL] [Abstract][Full Text] [Related]
13. Mammary Paget's disease and associated carcinoma. An immunohistochemical study.
Cohen C; Guarner J; DeRose PB
Arch Pathol Lab Med; 1993 Mar; 117(3):291-4. PubMed ID: 7680194
[TBL] [Abstract][Full Text] [Related]
14. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical detection of estrogen receptors in mammary Paget cells.
Tani EM; Skoog L
Acta Cytol; 1988; 32(6):825-8. PubMed ID: 2849272
[TBL] [Abstract][Full Text] [Related]
18. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
19. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
20. The routine immunohistochemical evaluation in Paget disease of the nipple.
Marczyk E; Kruczak A; Ambicka A; Mularz K; Harazin-Lechowska A; Moskal J; Sokołowski A; Mituś J; Ryś J
Pol J Pathol; 2011 Dec; 62(4):229-35. PubMed ID: 22246908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
